These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15012646)

  • 1. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection.
    Moyle GJ; Lysakova L; Brown S; Sibtain N; Healy J; Priest C; Mandalia S; Barton SE
    HIV Med; 2004 Mar; 5(2):82-7. PubMed ID: 15012646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy.
    Burgess CM; Quiroga RM
    J Am Acad Dermatol; 2005 Feb; 52(2):233-9. PubMed ID: 15692467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy.
    Moyle GJ; Brown S; Lysakova L; Barton SE
    HIV Med; 2006 Apr; 7(3):181-5. PubMed ID: 16494632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients.
    Lafaurie M; Dolivo M; Porcher R; Rudant J; Madelaine I; Molina JM
    J Acquir Immune Defic Syndr; 2005 Apr; 38(4):393-8. PubMed ID: 15764955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polylactic acid vs. polyacrylamide hydrogel for treatment of facial lipoatrophy: a randomized controlled trial [Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 132 SMILE].
    Lafaurie M; Dolivo M; Girard PM; May T; Bouchaud O; Carbonnel E; Madelaine I; Loze B; Porcher R; Molina JM;
    HIV Med; 2013 Aug; 14(7):410-20. PubMed ID: 23432777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients.
    Loutfy MR; Raboud JM; Antoniou T; Kovacs C; Shen S; Halpenny R; Ellenor D; Ezekiel D; Zhao A; Beninger F
    AIDS; 2007 May; 21(9):1147-55. PubMed ID: 17502725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA.
    Valantin MA; Aubron-Olivier C; Ghosn J; Laglenne E; Pauchard M; Schoen H; Bousquet R; Katz P; Costagliola D; Katlama C
    AIDS; 2003 Nov; 17(17):2471-7. PubMed ID: 14600518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy].
    Piquet M; Brignol L; Chatelain B; Rey D; Ricbourg B; Meyer C
    Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):496-504. PubMed ID: 17675198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy.
    Carey DL; Baker D; Rogers GD; Petoumenos K; Chuah J; Easey N; Machon K; Cooper DA; Emery S; Carr A;
    J Acquir Immune Defic Syndr; 2007 Dec; 46(5):581-9. PubMed ID: 18193500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly-L-lactic acid.
    Perry CM
    Am J Clin Dermatol; 2004; 5(5):361-6; discussion 367-8. PubMed ID: 15554738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up.
    Carey D; Baker D; Petoumenos K; Chuah J; Rogers GD; Watson J; Cooper DA; Emery S; Carr A;
    HIV Med; 2009 Mar; 10(3):163-72. PubMed ID: 19245538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy.
    Cattelan AM; Bauer U; Trevenzoli M; Sasset L; Campostrini S; Facchin C; Pagiaro E; Gerzeli S; Cadrobbi P; Chiarelli A
    Arch Dermatol; 2006 Mar; 142(3):329-34. PubMed ID: 16549708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients.
    Duracinsky M; Leclercq P; Herrmann S; Christen MO; Dolivo M; Goujard C; Chassany O
    BMC Infect Dis; 2014 Sep; 14():474. PubMed ID: 25178390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate versus delayed surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy: a randomized open-label study.
    Narciso P; Bucciardini R; Tozzi V; Bellagamba R; Ivanovic J; Giulianelli M; Scevola S; Palummieri A; Fragola V; Massella M; Fracasso L; De Vita R; Pierro P; Del Maestro A; Mirra M; Weimer L
    AIDS Res Hum Retroviruses; 2009 Oct; 25(10):979-87. PubMed ID: 19795984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Polylactic acid injections (Newfill) in the treatment of facial lipodystrophy in HIV-positive patients].
    Bodokh I; Simonet P
    Ann Dermatol Venereol; 2006 May; 133(5 Pt 1):429-32. PubMed ID: 16760828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The face of HIV and AIDS: can we erase the stigma?
    Kavouni A; Catalan J; Brown S; Mandalia S; Barton SE
    AIDS Care; 2008 Apr; 20(4):485-7. PubMed ID: 18449827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of facial lipoatrophy in HIV-infected patients.
    Prescrire Int; 2008 Aug; 17(96):170. PubMed ID: 19492497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly-L-lactic acid injection for HIV-associated facial lipoatrophy: treatment principles, case studies, and literature review.
    Kates LC; Fitzgerald R
    Aesthet Surg J; 2008; 28(4):397-403. PubMed ID: 19083552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study.
    Guaraldi G; Orlando G; De Fazio D; De Lorenzi I; Rottino A; De Santis G; Pedone A; Spaggiari A; Baccarani A; Borghi V; Esposito R
    Antivir Ther; 2005; 10(6):753-9. PubMed ID: 16218175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.